Market Access Preparing for the pharma fraud enforcement surge Here is what robust, risk-based compliance looks like in 2026.
News In fiery SOTU, Biden proclaims “We finally beat big pharma” Just days after the US presidential race officially narrowed to a contest between President Joe Biden and former president Donald Trump, it’s no surprise that Biden’s State of the Union spe
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.